Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through our partnership with the University of Mississippi.
Quote | Nemus Bioscience Inc. (OTCMKTS:NMUS)
Last: | $ |
---|---|
Change Percent: | -9.52% |
Open: | $0.7185 |
Close: | $0.65 |
High: | $0.7189 |
Low: | $0.60 |
Volume: | 1,004,500 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Nemus Bioscience Inc. (OTCMKTS:NMUS)
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing LONG BEACH, CA, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bios...
Burbank, CA, March 18, 2019 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG, “Imaging3” or the “Company”), a development stage company introducing disruptive technologies in the medical imaging industry, is updating and clarifying last week’s announcement t...
Message Board Posts | Nemus Bioscience Inc. (OTCMKTS:NMUS)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Nemus Bioscience Inc. Company Name:
NMUS Stock Symbol:
OTCMKTS Market:
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing LONG BEACH, CA, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bios...
Burbank, CA, March 18, 2019 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG, “Imaging3” or the “Company”), a development stage company introducing disruptive technologies in the medical imaging industry, is updating and clarifying last week’s announcement t...
NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations at the 31 st Annual ROTH Con...